Your browser doesn't support javascript.
loading
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Marinis, Filippo de; Wu, Yi-Long; de Castro, Gilberto; Chang, Gee-Chen; Chen, Yuh-Min; Cho, Byoung Chul; Freitas, Helano C; Jiang, Liyan; Kim, Sang-We; Martin, Claudio; Metro, Giulio; Provencio, Mariano; Vansteenkiste, Johan; Vicente, David; Zhou, Qing; Miranda, Miguel F; Bakker, Nicolaas A; Rigas, James R; Cheema, Parneet K.
Afiliação
  • Marinis F; Department of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Wu YL; Department of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, & Guangdong Academy of Medical Sciences, Guangzhou, PR China.
  • de Castro G; Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
  • Chang GC; Department of Internal Medicine, Division of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Chen YM; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
  • Cho BC; Department of Chest Medicine, Taipei Veterans General Hospital, & School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan.
  • Freitas HC; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Jiang L; Department of Medical Oncology, AC Camargo Cancer Center, São Paulo, Brazil.
  • Kim SW; Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China.
  • Martin C; Department of Oncology, Brain Tumor Center, Center for Personalized Cancer Medicine, Lung Cancer Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Metro G; Department of Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Provencio M; Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
  • Vansteenkiste J; Department of Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, IDHIPSA, Universidad Autónoma de Madrid, Spain.
  • Vicente D; Department of Respiratory Diseases, Respiratory Oncology Unit, University Hospitals KU Leuven, Leuven, Belgium.
  • Zhou Q; Department of Clinical Oncology, H.U.V. Macarena, Seville, Spain.
  • Miranda MF; Department of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, & Guangdong Academy of Medical Sciences, Guangzhou, PR China.
  • Bakker NA; AstraZeneca, Biometrics & Information Sciences, Cambridge, UK.
  • Rigas JR; AstraZeneca, Oncology Business Unit, Medical, Cambridge, UK.
  • Cheema PK; AstraZeneca, GMA Oncology TA, Gaithersburg, MD 20878, USA.
Future Oncol ; 15(26): 3003-3014, 2019 Sep.
Article em En | MEDLINE | ID: mdl-31339357
Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. We report real-world effectiveness and safety data. Patients & methods: EGFR T790M positive advanced non-small-cell lung cancer adults, who received ≥1 prior EGFR tyrosine kinase inhibitor, received osimertinib 80 mg daily. Primary effectiveness outcome: overall survival. Secondary effectiveness outcomes included: investigator-assessed clinical response, progression-free survival, time-to-treatment discontinuation. Results: At data cutoff, 3015 patients had enrolled: 57.1% had investigator-assessed response (95% CI: 55.2-58.9). Median progression-free survival: 11.1 months (95% CI: 11.0-12.0) and median time-to-treatment discontinuation: 13.5 months (95% CI: 12.6-13.9). Interstitial lung disease/pneumonitis-like events reported in 28 (1%) patients. Conclusion: Osimertinib demonstrated clinical effectiveness similar to efficacy observed in the clinical trial program with no new safety signals.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Compostos de Anilina / Neoplasias Pulmonares / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Compostos de Anilina / Neoplasias Pulmonares / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália